Ignite Creation Date:
2024-05-05 @ 4:52 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00334074
Status:
COMPLETED
Last Update Posted:
2013-07-17
First Post:
2006-06-02
Brief Title:
Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS
Sponsor:
Baylor Research Institute
Organization:
Baylor Research Institute
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Chronic Myelogenous Leukemia |
| Acute Myelogenous Leukemia |
| Myelodysplastic Syndromes |
Keywords:
| Name | View |
|---|---|
| AML | View |
| MDS | View |
| CML | View |
| Relapsed | View |
| Refractory | View |
| Chemo treatment | View |
| Clofarabine | View |
| Cytarabine | View |
| standard or poor cytogenetic risk AML | View |
| untreated high-risk 10 blasts MDS | View |
| CML in accelerated phase or blast crisis | View |
| Elderly AML patients with risk of anthracycline toxicity | View |